SPOTLIGHT: Crucell, MedImmune strike deal


Dutch biotech Crucell has inked a joint venture deal with MedImmune to develop its bacterial antibodies to treat hospital-acquired infections. MedImmune has agreed to provide upfront, annual and milestone fees that could exceed $40 million. Release